Regenxbio (RGNX) announced the completion of enrollment in the Atmosphere and Ascent pivotal studies evaluating surabgene lomparvovec in wet age-related macular degeneration using subretinal delivery. Topline data is expected in the fourth quarter of 2026.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Promising Data and Regulatory Progress Bolster Buy Rating for RegenXBio’s RGX-121
- Promising Data and Strategic Moves Position RegenXBio for Potential Success with RGX-121
- Regenxbio reports ‘positive’ results from Phase I/II/III CAMPSIITE trial
- Regenxbio FDA delay ‘not a needle mover,’ says Leerink
- Strategic Developments and Partnerships Bolster RegenXBio’s Buy Rating Amid Regulatory Delay